SAN.PA - Sanofi

Paris - Paris Delayed Price. Currency in EUR
74.67
-0.45 (-0.60%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close75.12
Open74.97
Bid0.00 x 0
Ask0.00 x 0
Day's Range74.24 - 75.33
52 Week Range62.88 - 86.39
Volume2,747,102
Avg. Volume2,293,969
Market Cap92.465B
Beta0.68
PE Ratio (TTM)27.02
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.03 (4.01%)
Ex-Dividend Date2018-05-11
1y Target EstN/A
  • A Look at Shire’s Valuation on September 19
    Market Realist6 hours ago

    A Look at Shire’s Valuation on September 19

    Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.

  • The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
    Zacks14 hours ago

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

  • Reuters3 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (£1.3 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.

  • Reuters3 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. The French drugmaker, hurt by declining revenue at its diabetes business in recent years, is eyeing a return to growth from the second half of 2018 as it builds upon acquisitions made earlier this year. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday.

  • Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
    Zacks3 days ago

    Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis

    Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.

  • Analyzing uniQure’s Valuation Trend
    Market Realist6 days ago

    Analyzing uniQure’s Valuation Trend

    Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.

  • 5 Problematic Stocks Francis Chou Dared To Buy
    Insider Monkey6 days ago

    5 Problematic Stocks Francis Chou Dared To Buy

    Francis Chou, a well-regarded Canadian value investor,  the founder of Chou Associates Management, and Morningstar Fund Manager of the Decade in 2004, was once just an ordinary immigrant in Canada with $200 in his pocket. Even though he is Chinese, he was born and raised in India, and came to Canada looking for a job. For […]

  • Sanofi pledges to keep up its restructuring efforts
    Reuters7 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (1.33 billion pounds) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.

  • Reuters7 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. The French drugmaker, hurt by declining revenue at its diabetes business in recent years, is eyeing a return to growth from the second half of 2018 as it builds upon acquisitions made earlier this year. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday.

  • Bayer's pharma unit head Weinand quits to join Sanofi
    Reuters8 days ago

    Bayer's pharma unit head Weinand quits to join Sanofi

    Bayer, which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.

  • Bayer's pharma unit head Weinand quits to join Sanofi
    Reuters8 days ago

    Bayer's pharma unit head Weinand quits to join Sanofi

    Bayer (BAYGn.DE), which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi (SASY.PA) to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.

  • The Wall Street Journal8 days ago

    [$$] Sanofi Poaches Bayer Manager to Lead Unit

    Sanofi hired the head of Bayer’s pharmaceuticals division to lead its Primary Care unit, one of two new divisions that the French company is creating.

  • Sanofi and Bayer Are Swapping Executives
    Bloomberg8 days ago

    Sanofi and Bayer Are Swapping Executives

    Sanofi and Bayer AG, two European drugmakers with blockbuster medicines facing headwinds, are swapping top executives. Sanofi is bringing in Bayer’s Dieter Weinand as executive vice president in charge of a new unit that combines its diabetes and cardiovascular operations with a broader group of established products, the Paris-based company said in a statement Thursday. At the same time, Stefan Oelrich, head of diabetes at Sanofi, will replace Weinand as the head of Bayer’s pharmaceuticals division in November.

  • 3 Top Value Stocks to Buy Right Now
    Motley Fool8 days ago

    3 Top Value Stocks to Buy Right Now

    This power-packed list of value stocks from diverse industries is all you need to see right now.

  • Benzinga10 days ago

    BofA Upgrades Sanofi, Names 3 Growth Drivers For Pharma Stock

    Sanofi SA (ADR) (NYSE: SNY ), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical ...

  • Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
    Zacks13 days ago

    Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

    Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

  • Why Sangamo Therapeutics Stock Is Down More than 22% Today
    Market Realist15 days ago

    Why Sangamo Therapeutics Stock Is Down More than 22% Today

    Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. The stock is sliding after the company announced the results of its Phase 1/2 study data for its gene editing candidate SB-913. Sangamo Therapeutics had announced that it would release the results of its Champion study of SB-913 on August 30.

  • The Wall Street Journal16 days ago

    [$$] Sanofi Pays $25 Million to Settle Bribery Charges

    The alleged schemes spanned multiple countries and involved bribes to government procurement officials and health-care providers to receive tenders and increase prescriptions of the company’s products, the SEC said. The alleged payments violated the Foreign Corrupt Practices Act, which bars bribes of foreign officials for business purposes, the SEC said. The SEC said Sanofi violated the books-and-records and internal-control provisions of the FCPA.

  • Sanofi to pay more than $25 million to resolve corruption charges: SEC
    Reuters16 days ago

    Sanofi to pay more than $25 million to resolve corruption charges: SEC

    French pharmaceutical giant Sanofi will pay more than $25 million to settle charges that its Kazakhstan and Middle East subsidiaries made corrupt payments to win business, the top U.S. securities regulator ...

  • Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
    Zacks18 days ago

    Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe

    Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

  • Reuters18 days ago

    Sanofi wins European approval for rare blood-clotting disorder treatment

    French drugmaker Sanofi on Monday said it had secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in June had recommended the approval of caplacizumab, which is to be prescribed to adults suffering acquired thrombotic thrombocytopenic purpura (aTTP). The U.S Food & Drug Administration (FDA), which has granted the drug a 'Fast Track' designation, is expected to follow suit in early 2019.

  • Is Sanofi (EPA:SAN) Attractive At This PE Ratio?
    Simply Wall St.21 days ago

    Is Sanofi (EPA:SAN) Attractive At This PE Ratio?

    This article is intended for those of you who are at the beginning of your investing journey and want to learn about the link between company’s fundamentals and stock marketRead More...

  • Estimates and Recommendations for Novartis in August
    Market Realist22 days ago

    Estimates and Recommendations for Novartis in August

    Wall Street analysts are estimating that Novartis will report revenues of $52.4 billion during 2018, a 6.7% growth year-over-year compared to $49.1 billion during 2017. Analysts are estimating that its net income margin will decrease to 23% during 2018 compared to 23.2% during 2017, mainly due to an increase in overall selling, general, and administrative expenses and increased research and development expenses. Novartis stock has increased ~0.7% over the last 12 months and ~0.2% in 2018 year-to-date.

  • The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
    Zacks22 days ago

    The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross

    The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross

  • European Commission Approves Novartis’s Tafinlar/Mekinist Combo
    Market Realist22 days ago

    European Commission Approves Novartis’s Tafinlar/Mekinist Combo

    Novartis (NVS) announced on August 29 that the European Commission had approved the combination of its drugs Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of patients with stage III BRAF V600 mutation-positive melanoma. This was the third approval in Europe for the Tafinlar and Mekinist combination for the treatment of various tumor types.